chen Liang

Dr. chen Liang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2019 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
MWMiao-Yan Wei
Miao-Yan Wei
SSSi Shi
Si Shi
CLchen Liang
chen Liang
QMQingcai Meng
Qingcai Meng
JHJie Hua
Jie Hua
XYXianjun Yu
Xianjun Yu
Microbiota is just beginning to be recognized as an important player in carcinogenesis and the interplay among microbes is greater than expected. Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease for which mortality closely parallels incidence. Early detection would provide the best opportunity to increase survival rates. Specific well-studied oral, gastrointestinal, and intrapancreatic microbes and some kinds of hepatotropic viruses and bactibilia may have potential etiological roles in pancreatic carcinogenesis, or modulating individual responses to oncotherapy. Concrete mechanisms mainly involve perpetuating inflammation, regulating the immune system-microbe-tumor axis, affecting metabolism, and altering the tumor microenvironment. The revolutionary technology of omics has generated insight into cancer microbiomes. A better understanding of the microbiota in PDAC might lead to the establishment of screening or early-stage diagnosis methods, implementation of cancer bacteriotherapy, adjustment of therapeutic efficacy even alleviating the adverse effects, creating new opportunities and fostering hope for desperate PDAC patients.

1 December 2017 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
CLchen Liang
chen Liang
SSSi Shi
Si Shi
QMQingcai Meng
Qingcai Meng
DLDingkong Liang
Dingkong Liang
SJShunrong Ji
Shunrong Ji
XYXianjun Yu
Xianjun Yu
Pancreatic ductal adenocarcinoma (PDAC) is among the most devastating human malignancies. The poor clinical outcome in PDAC is partly attributed to a growth-permissive tumor microenvironment. In the PDAC microenvironment, the stroma is characterized by the development of extensive fibrosis, with stromal components outnumbering pancreatic cancer cells. Each of the components within the stroma has a distinct role in conferring chemoresistance to PDAC, and intrinsic chemoresistance has further worsened this pessimistic prognosis. The nucleoside analog gemcitabine (GEM) is usually the recommended first-line chemotherapeutic agent for PDAC patients and is given alone or in combination with other agents. The mechanisms of intrinsic resistance to GEM are an active area of ongoing research. This review highlights the important role the complex structure of stroma in PDAC plays in the intrinsic resistance to GEM and discusses whether antistroma therapy improves the efficacy of GEM. The addition of antistroma therapy combined with GEM is expected to be a novel therapeutic strategy with significant survival benefits for PDAC patients.

1 September 2017 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
QMQingcai Meng
Qingcai Meng
SSSi Shi
Si Shi
CLchen Liang
chen Liang
DLDingkong Liang
Dingkong Liang
WXWenyan Xu
Wenyan Xu
XYXianjun Yu
Xianjun Yu
Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis Qingcai Meng,1–3,* Si Shi,1–3,* Chen Liang,1–3,* Dingkong Liang,1–3 Wenyan Xu,1–3 Shunrong Ji,1–3 Bo Zhang,1–3 Quanxing Ni,1–3 Jin Xu,1–3 Xianjun Yu1–3 1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 2Department of Oncology, Shanghai Medical College, 3Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers and is increased in 30%–60% of patients with pancreatic cancer. Although carbohydrate antigen 19-9 (CA19-9) is the most important serum biomarker in pancreatic cancer, the diagnostic and prognostic value of CEA is gradually being recognized.Materials and methods: The MEDLINE, EMBASE, and Web of Science databases were searched for related literature published until January 2017. Diagnostic accuracy variables were pooled using the Meta-Disc software. The pooled hazard ratios (HRs) for prognostic data were calculated and analyzed using Stata software.Results: A total of 3,650 participants enrolled in 19 studies met our inclusion criteria. The pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of a CEA-based panel were 0.45 (95% confidence interval [CI], 0.41–0.50), 0.89 (95% CI, 0.86–0.91), 5.39 (95% CI, 3.16–9.18), and 0.55 (95% CI, 0.41–0.72), respectively. The area under the curve (AUC, 0.90) and Q-value (0.84) of the CEA-based panel indicated a significantly higher diagnostic accuracy compared with CEA or CA19-9 alone. Moreover, there was also a significant association between high levels of CEA and worse overall survival (HR, 1.43; 95% CI, 1.31–1.56).Conclusion: Our meta-analysis indicated that elevated serum CEA level, as a vital supplementary to CA19-9, can play an important role in the clinical diagnosis of pancreatic cancer patients and predict poor prognosis. Keywords: carcinoembryonic antigen, pancreatic cancer, diagnosis, prognosis, meta-analysis

1 April 2016 in Cancer Letters
Verified
Journal Article
Closed access
SJShunrong Ji
Shunrong Ji
BZBo Zhang
Bo Zhang
JLJiang Liu
Jiang Liu
YQYi Qin
Yi Qin
CLchen Liang
chen Liang
XYXianjun Yu
Xianjun Yu

6 July 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
QMQingcai Meng
Qingcai Meng
SSSi Shi
Si Shi
CLchen Liang
chen Liang
DLDingkong Liang
Dingkong Liang
JHJie Hua
Jie Hua
XYXianjun Yu
Xianjun Yu

1 May 2019 in Annals of Surgery
Verified
Journal Article
Closed access
SSSi Shi
Si Shi
JHJie Hua
Jie Hua
CLchen Liang
chen Liang
QMQingcai Meng
Qingcai Meng
DLDingkong Liang
Dingkong Liang
XYXianjun Yu
Xianjun Yu
Objective: The aim of this study was to improve the 8th edition (8th) of the American Joint Committee on Cancer (AJCC) staging system for pancreatic ductal adenocarcinoma (PDAC). Background: The new 8th AJCC staging system for PDAC was released in October, 2016, and will be applied in clinical practice in 2018. Methods: Two large cohorts were included in this analysis. One consisted of 45,856 PDAC patients in the Surveillance, Epidemiology, and End Results (SEER) database (2004–2014), and the other consisted of 3166 PDAC patients in the Fudan University Shanghai Cancer Center (FUSCC) database (2005–2015). Results: Using the 8th AJCC staging system, the median overall survival of the patients in the same stage varied widely among the different substages. We proposed a modified staging system based on median OS in which we maintained the T, N, and M definitions, but regrouped the substages. In the SEER cohort, the concordance index was higher for local disease with the modified staging system [0.637; 95% confidence interval (CI) 0.631–0.642] than with the 8th AJCC staging system (0.620, 95% CI 0.615–0.626). Similar findings were also observed in the FUSCC cohort. In addition, we verified the reliability of the modified staging system in an analysis of patients with different examined lymph node counts (≥15 or 1–14). Conclusions: The modified 8th AJCC staging system for PDAC proposed in this study provides improvements and may be evaluated for potential adoption in the next edition.